Maiken Keson Brookes Rubius Therapeutics, Inc. (RUBY) insider trading activity

Maiken Keson Brookes is CLO & Corp. Secretary of Rubius Therapeutics, Inc.. Currently has a direct ownership of 5,343 shares of RUBY, which is worth approximately $0. The most recent transaction as insider was on Feb 01, 2022, when has been sold 2,732 shares (Common Stock) at a price of $6.57 per share, resulting in proceeds of $17,949. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 5.34K

0% 3M change

0% 12M change

Total Value Held $0

Maiken Keson-Brookes Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 01 2022	SELL Open market or private sale	$17,949 $6.57 p/Share	2,732 Reduced 33.83%	5,343 Common Stock
Jan 29 2022	BUY Exercise of conversion of derivative security	-	8,075 Added 50.0%	8,075 Common Stock
Mar 15 2021	SELL Open market or private sale	$506,000 $20.24 p/Share	25,000 Reduced 100.0%	0 Common Stock
Mar 15 2021	BUY Exercise of conversion of derivative security	$192,500 $7.7 p/Share	25,000 Added 50.0%	25,000 Common Stock

Also insider at

MURA

Mural Oncology plc